A phase 3, global, multi-center, double-blind, randomized, efficacy study of IMAB362 Plus mFOLFOX6 compared with placebo plus mFOLFOX6 as first-line treatment of subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) Adenocarcinoma. SPOTLIGHT.

  • Strickland, Andrew (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

Monash Health Ref: RES-18-000-271A
Protocol number: 8951-CL-0301
Effective start/end date2/10/181/10/21